10 completed, 4 unknown. 14 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 10, Unknown 4 |
| Phase 2 | 1 | Completed 1 |
Follow Type II Diabetes: new trials by email Literature Review of Type II Diabetes trials Research Report on Type II Diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects PS1, Placebo - Type II Diabetes | Phase 1 | Completed | Pharmasaga Co. Ltd. | 75 | 2023-12-22 | 2026-07-07 |
| Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults CKD-378 (low-dose) - Type II Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 23 | 2023-06-01 | 2023-12-19 |
| A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378 CKD-378, QD, PO Drug: D745, D150, QD, PO - Type II Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 24 | 2023-04-11 | 2024-03-12 |
| A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR, T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR - Type II Diabetes | Phase 1 | Unknown | Shandong Suncadia Medicine Co., Ltd. | 80 | 2021-11-09 | 2021-11-04 |
| A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers FDC tablet - Type II Diabetes | Phase 1 | Unknown | Shandong Suncadia Medicine Co., Ltd. | 28 | 2021-10-13 | 2021-11-24 |
| A Study to Investigate the PK and Safety of CKD-393 CKD-393 formulation I, CKD-393 formulation II, D501, D759, H053 - Type II Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 26 | 2021-03-26 | 2021-08-02 |
| Mass Balance and Biotransformation of [14C]HSK7653 in Human [14C]HSK7653 - Type II Diabetes | Phase 1 | Completed | Sichuan Haisco Pharmaceutical Group Co., Ltd | 6 | 2020-11-15 | 2022-12-12 |
| Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults CKD-387, D484 - Type II Diabetes | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 36 | 2018-08-30 | 2018-08-24 |
| Clinical Trial for PB-119 in Healthy Subjects (Phase I) PB-119 - Type II Diabetes | Phase 1 | Completed | PegBio Co., Ltd. | 70 | 2014-02-01 | 2017-02-14 |
| Using EEG Operant Conditioning to Improve Trait Self-Control and Promote Healthy Behavior STRIDES, Sham Control - Obesity, Type II Diabetes | Phase 1 | Completed | University of Rochester | 16 | 2013-02-01 | 2015-04-30 |
| Effects of Purple Vegetables on Cardiovascular Disease (CVD) Risk Factors vegetable - Hypertension, Hypercholesterolemia | Phase 1 | Unknown | University of Guelph | 60 | 2012-04-01 | 2016-10-26 |
| Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Placebo, Sitagliptin, LEZ763 - Type II Diabetes | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 220 | 2012-03-01 | 2020-12-17 |
| To Evaluate 24-hr Glucose After OD vs BD AZD1656 AZD1656 - Type II Diabetes | Phase 1 | Completed | AstraZeneca | 36 | 2009-01-01 | 2009-05-07 |
| To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC, GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb - Type II Diabetes | Phase 1 | Completed | Sandoz | 16 | 2001-06-01 | 2017-03-29 |
Diabetes Mellitus, Type 2 (14) · Obesity (2) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Health Behavior (1) · Hypercholesterolemia (1) · Hypertension (1) · Inflammation (1) · Insulin Resistance (1) · Metabolic Syndrome (1)
Endocrine System Diseases (14) · Glucose Metabolism Disorders (14) · Metabolic Diseases (14) · Nutritional and Metabolic Diseases (14) · Diabetes Mellitus (13) · Body Weight (2) · Nutrition Disorders (2) · Overnutrition (2) · Overweight (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Behavior (1) · Cardiovascular Diseases (1)
Metformin (2) · AZD1656 (1) · Sitagliptin Phosphate (1) · Vegetables (1)
Chong Kun Dang Pharmaceutical (4) · Shandong Suncadia Medicine Co., Ltd. (2) · AstraZeneca (1) · Novartis Pharmaceuticals (1) · PegBio Co., Ltd. (1) · Pharmasaga Co. Ltd. (1) · Sandoz (1) · Sichuan Haisco Pharmaceutical Group Co., Ltd (1) · University of Guelph (1) · University of Rochester (1)
South Korea (4) · China (3) · United States (3) · Canada (1) · Taiwan (1)
Emanuel P DeNoia, M.D (1) · Jordan Silberman, PhD (1) · Klas Malmberg, MD, PhD, Prof., (1) · Liyan Miao, PhD (1) · Min Soo Park, MD, Ph.D (1) · Min Soo Park, Ph.D. (1) · Mingche Liu, MD., PhD (1) · So Ran Hong, M.D. (1) · Yuan Lv, Doctor (1)